Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 1

4340 - Short-term outcomes of cancer patients with pulmonary embolism according to the setting (hospital-acquired vs. outpatient) at diagnosis.


28 Sep 2019


Poster Display session 1


Supportive Care and Symptom Management

Tumour Site


Diego Muñoz Guglielmetti


Annals of Oncology (2019) 30 (suppl_5): v718-v746. 10.1093/annonc/mdz265


D. Muñoz Guglielmetti1, D. Pesántez2, F. Posch3, C. Ay4, M. Aramberri5, M.D.C. Beato Zambrano6, C. Diaz-Pedroche5, C. Font7

Author affiliations

  • 1 Radiation Oncology, Hospital Clinic y Provincial de Barcelona, 08036 - Barcelona/ES
  • 2 Dept. Oncology, Hospital Clinic y Provincial de Barcelona, 08014 - Barcelona/ES
  • 3 Internal Medicine, Medical University of Graz, 8036 - Graz/AT
  • 4 Clinical Division Of Hematology And Hemostaseology, Medizinische Universitaet Wien (Medical University of Vienna), 1090 - Vienna/AT
  • 5 Internal Medicine, Hospital Universitario 12 de Octubre, 28041 - Madrid/ES
  • 6 Medical Oncology, Hospital Universitario Virgen Macarena, 41009 - Sevilla/ES
  • 7 Dept. Oncology, Hospital Clinic y Provincial de Barcelona, 08036 - Barcelona/ES


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 4340


Pulmonary embolism (PE) is a common condition in patients with cancer, having a wide spectrum of clinical presentation (from acute life-threatening to truly asymptomatic incidental events). The aim of this study was to assess the prognostic relevance of the variable ‘setting’ (hospital-acquired vs. outpatient) at PE diagnosis.


Multicenter observational ongoing registry of consecutive patients with cancer-associated PE (2005-2018) including incidental and acute symptomatic events. The main outcome measured was the rate of overall and PE-specific 30-day mortality. Secondary outcomes were: rates of 30-day major bleeding (MB) and venous thromboembolism (VTE) recurrence.


We included a total of 617 patients (61.6% male; median age 65 + 11.4 years; range 19-91 years) including N = 522 (85%) outpatients and N = 95 (15%) inpatients at PE diagnosis. The most frequent primary tumors were: lung 32%, colorectal 14%, urologic 13%, upper GI 12%, breast 9%, gynecologic 6% and other 9%). Most of the patients (79%) had metastatic cancer and nearly half (47%) were receiving chemotherapy.The PE was incidentally found in 54% of the cases. Overall 30-day mortality occurred in 95 patients (15% of the cohort), being greater in inpatients compared to outpatients (30% vs. 13%; p < 0.0001). Only 13 patients presented PE-related mortality (3% of the cohort), with no significant differences according to the setting at PE diagnosis (3.2% in inpatients vs. 1.7% in outpatients; p = 0.352). Similarly, there were no differences in 30-day MB (7.4% in inpatients vs. 4.4% in outpatients; p = 0.217) or VTE recurrence (4.2% in inpatients vs. 3.3% in outpatients; p = 0.637) according to the setting at PE diagnosis.


Hospital-acquired PE in cancer patients was associated with a greater overall 30-day mortality compared to outpatients at PE diagnosis. This finding may be relevant for the development of PE risk-assessment models in this setting.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Hospital Clínic de Barcelona.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.